Ionis Pharmaceuticals Inc. (NASDAQ:IONS) rose 5.3% during trading on Tuesday . The stock traded as high as $33.50 and last traded at $33.31, with a volume of 1,120,502 shares traded. The stock had previously closed at $31.64.

IONS has been the topic of several research analyst reports. Wells Fargo & Co. restated an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Friday, August 19th. Needham & Company LLC restated a “buy” rating and set a $55.00 target price (down from $88.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, May 26th. JPMorgan Chase & Co. decreased their target price on shares of Ionis Pharmaceuticals from $53.00 to $25.00 and set a “neutral” rating on the stock in a research report on Friday, May 27th. BMO Capital Markets restated a “market perform” rating and set a $26.00 target price on shares of Ionis Pharmaceuticals in a research report on Tuesday, June 7th. Finally, Jefferies Group restated an “underperform” rating and set a $12.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, July 15th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Ionis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $41.82.

The stock has a 50 day moving average price of $32.86 and a 200 day moving average price of $32.55. The stock’s market capitalization is $4.06 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/ionis-pharmaceuticals-inc-ions-stock-price-up-5-3.html

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Tuesday, August 9th. The company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.05. Ionis Pharmaceuticals had a negative return on equity of 126.88% and a negative net margin of 128.94%. The business earned $38.50 million during the quarter, compared to analysts’ expectations of $38.52 million. The business’s quarterly revenue was down 68.0% compared to the same quarter last year. On average, equities analysts expect that Ionis Pharmaceuticals Inc. will post ($1.07) earnings per share for the current fiscal year.

In related news, COO B Lynne Parshall sold 12,500 shares of the stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $29.88, for a total value of $373,500.00. Following the completion of the transaction, the chief operating officer now owns 25,558 shares in the company, valued at approximately $763,673.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.86% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in Ionis Pharmaceuticals by 4.4% in the first quarter. Geode Capital Management LLC now owns 760,951 shares of the company’s stock worth $30,802,000 after buying an additional 31,981 shares during the period. State Street Corp raised its position in Ionis Pharmaceuticals by 15.7% in the first quarter. State Street Corp now owns 3,037,388 shares of the company’s stock worth $123,010,000 after buying an additional 412,515 shares during the period. Broderick Brian C raised its position in Ionis Pharmaceuticals by 25.4% in the second quarter. Broderick Brian C now owns 24,444 shares of the company’s stock worth $570,000 after buying an additional 4,949 shares during the period. Motley Fool Asset Management LLC raised its position in Ionis Pharmaceuticals by 600.0% in the first quarter. Motley Fool Asset Management LLC now owns 140,000 shares of the company’s stock worth $5,670,000 after buying an additional 120,000 shares during the period. Finally, Motley Fool Wealth Management LLC raised its position in Ionis Pharmaceuticals by 51.1% in the first quarter. Motley Fool Wealth Management LLC now owns 166,513 shares of the company’s stock worth $6,744,000 after buying an additional 56,320 shares during the period. Institutional investors and hedge funds own 89.58% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.

5 Day Chart for NASDAQ:IONS

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.